A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis

Eva Rombout-Sestrienkova, Bjorn Winkens, Marian van Kraaij, Cees Th B M van Deursen, Mirian C H Janssen, Alexander M J Rennings, Dorothea Evers, Jean-Louis Kerkhoffs, Ad Masclee, Ger H Koek, Eva Rombout-Sestrienkova, Bjorn Winkens, Marian van Kraaij, Cees Th B M van Deursen, Mirian C H Janssen, Alexander M J Rennings, Dorothea Evers, Jean-Louis Kerkhoffs, Ad Masclee, Ger H Koek

Abstract

Background and aims: Standard treatment for naïve hereditary hemochromatosis patients consists of phlebotomy or a personalized erythrocytapheresis. Erythrocytapheresis is more efficient, but infrequently used because of perceived costs and specialized equipment being needed. The main aim of our study was to develop a model that predicts the number of initial treatment procedures for both treatment methods. This information may help the clinician to select the optimal treatment modality for the individual patient.

Methods: We analyzed retrospective data of 125 newly diagnosed patients (C282Y homozygous), treated either with phlebotomy (n = 54) or erythrocytapheresis (n = 71) until serum ferritin (SF) reached levels ≤100 μg/L. To estimate the required number of treatment procedures multiple linear regression analysis was used for each treatment method separately.

Results: The linear regression model with the best predictive quality (R2 = 0.74 and 0.73 for erythrocytapheresis and phlebotomy respectively) included initial SF, initial hemoglobin (Hb) level, age, and BMI, where initial SF was independently related to the total number of treatment procedures for both treatment methods. The prediction error expressed in RMSPE and RMSDR was lower for erythrocytapheresis than for phlebotomy (3.8 and 4.1 vs 7.0 and 8.0 respectively), CONCLUSIONS: Although the prediction error of the developed model was relatively large, the model may help the clinician to choose the most optimal treatment method for an individual patient. Generally erythrocytapheresis halves the number of treatment procedures for all patients, where the largest reduction (between 55% and 64%) is reached in patients with an initial Hb level ≥ 9 mmol/L (14.5 g/dL). ClinicalTrials.gov number NCT00202436.

Keywords: erythrocytapheresis; hereditary hemochromatosis; phlebotomy; prediction rule.

Conflict of interest statement

The authors declare that they have no conflicts of interest relevant to the manuscript submitted to Journal of Clinical Apheresis.

© 2020 The Authors. Journal of Clinical Apheresis published by Wiley Periodicals LLC.

Figures

FIGURE 1
FIGURE 1
A, Observed versus predicted number of treatment procedures using erythrocytapheresis as treatment modality. Predicted numbers are based on model B, using initial SF, initial Hb count, age and BMI as predictors. (R2 = 0.74; RMSPE = 3.8; RMSDR = 4.1). The Y = X line is presented, where points on this line imply that the predicted and observed numbers were the same. B, Observed vs predicted number of treatment procedures using phlebotomy as treatment modality. Predicted numbers are based on model B, using initial SF, initial Hb count, age and BMI as predictors (R2 = 0.73; RMSPE = 7.0; RMSDR = 8.0). The Y = X line is presented, where points on this line imply that the predicted and observed numbers were the same

References

    1. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139:393‐408.
    1. Ellervik C, Birgens H, Tybjaerg‐Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta‐analyses including 66 000 cases and 226 000 controls. Hepatology. 2007;46:1071‐1080.
    1. Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010;116:317‐325.
    1. Rombout‐Sestrienkova E, van Kraaij MG, Koek GH. How we manage patients with hereditary hemochromatosis. Br J Haematol. 2016;175(5):759‐770.
    1. Ong SY, Gurrin LC, Dolling L, et al. Reduction of body iron in HFE‐related haemochromatosis and moderate iron overload (Mi‐iron): a multicenter, participant‐blinded, randomized controlled trial. Lancet Haematol. 2017;4:e 607‐e 614.
    1. Prabhu A, Cargill T, Roberts N, Ryan JD. Systemic review of the clinical outcomes of iron reduction in Hereditary hemochromatosis. Hepatology. 2020;72:1469‐1482. 10.1002/HEP.31405.
    1. European Association for the study of the Liver . EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53:3‐22.
    1. Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American association for the study of liver diseases. Hepatology. 2011;54:328‐343.
    1. Brissot P, Ball S, Rofail D, Cannon H, Jin VW. Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment. Transfusion. 2011;51:1331‐1338.
    1. Rombout‐Sestrienkova E, Nieman FHM, Essers BAB, et al. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis: results from a randomised trial. Transfusion. 2012;52:470‐477.
    1. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice‐evidence‐based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher. 2019;34:171‐354.
    1. Sundic T, Hervig T, Hannisdal S, et al. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis. Blood Transfus. 2014;12(Suppl 1):s84‐s89.
    1. Conte D, Brunelli L, Bozzani A, Tidone L, Quatrini M, Bianchi PA. Erythrocytapheresis in idiopathic haemochromatosis. Br Med J (Clin Res Ed). 1983;286:939.
    1. Zoller WG, Kellner H, Spengel FA. Erythrocytapheresis. A method for rapid extracorporeal elimination of erythrocytes. Results in 65 patients. Klin Wochenschr. 1988;66:404‐409.
    1. Conte D, Mandelli C, Cesana M, Ferrini R, Marconi M, Bianchi A. Effectiveness of erythrocytapheresis in idiopathic hemochromatosis. Report of 14 cases. Int J Artif Organs. 1989;12:59‐62.
    1. Kellner H, Zoller WG. Repeated isovolemic large‐volume erythrocytapheresis in the treatment of idiopathic hemochromatosis. Z Gastroenterol. 1992;30:779‐783.
    1. Kohan A, Niborski R, Daruich J, et al. Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative. Vox Sang. 2000;79:40‐45.
    1. Muncunill J, Vaquer P, Galmes A, et al. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apher. 2002;17:88‐92.
    1. Mariani R, Pelucchi S, Perseghin P, Corengia C, Piperno A. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica. 2005;90:717‐718.
    1. Fernandez‐Mosteirin N, Salvador‐Osuna C, Garcia‐Erce JA, et al. Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations. Med Clin (Barc). 2006;127:409‐412.
    1. Wijermans P, van Egmond L, Ypma P, et al. Isovolemic erythrocytapheresis technique as an alternative to conventional phlebotomy in patients with polycythemia rubra vera and hemochromatosis. Transfus Apher Sci. 2009;40:137.
    1. Poullin P, Lefevre PA. Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases. Transfus Clin Biol. 2011;18:553‐558.
    1. Evers D, Kerkhoffs JL, van Egmond L, Schipperus MR, Wijermans PW. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis. J Clin Apher. 2014;29:133‐138.
    1. Swinkels DW, Jorna AT, Raymakers RA. Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis. Neth J Med. 2007;65:452‐455.
    1. Panch SR, Yau YY, West K, Diggs K, Sweigart T, Leitman SF. Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload. Transfusion. 2015;55:611‐622.
    1. Verhaegh PLM, Moris W, Koek GH, van Deursen CTBM. The modified iron avidity index: a promising phenotypic predictor in HFE‐related haemochromatosis. Liver Int. 2016;36(10):1535‐1539.
    1. Rombout‐Sestrienkova E, Winkens B, Essers BAB, et al. Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients; results from a randomized cross/over trial. Transfusion. 2016;56:261‐270.
    1. Adams PC. Factors affecting the rate of iron mobilization during venesection therapy for genetic hemochromatosis. Am J Hematol. 1998;58:16‐19.
    1. Manet G, Bardou‐Jacquet E, Perrin M, et al. The iron reabsorption index: a new phenotypic and pathophysiological descriptor in HFE hemochromatosis. Eur J Gastroenterol Hepatol. 2013;25:1321‐1329.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel